SignaBlok has received Orphan Drug Designation from the FDA for TREM-1 inhibitor, its investigative therapeutic for the treatment of retinopathy of prematurity (ROP)
Let’s start with a look at SignaBlok.
Operating out of Massachusetts, the early-stage biotechnology company specializes in developing preclinical targeted therapeutics and delivery nanosystems for inflammatory and immune-based diseases (such as ROP).
How it’s doing this: Via two key proprietary technologies:
- A novel model of cell signaling called Signaling Chain HOmoOLiguomerization (SCHOOL) that creates peptide inhibitors targeting immune receptor signaling.
- One such receptor is TREM-1 (see below)
- A targeted peptide delivery platform that packages SCHOOL-designed peptides into lipopeptide complexes or nanoparticle–like carriers.
Before we talk tech, explain this TREM-1 inhibitor.
First, a look at the Triggering receptor expressed on myeloid cells 1 (TREM-1) receptor.
- What it does: Plays a critical role in ROP development by magnifying inflammatory responses in innate immune cells (such as macrophages)—and is challenging to clinically target “due to multiple and unknown TREM-1 ligands.”
Enter in the TREM-1 inhibitor: This is designed to address that challenge via a “new, ligand-independent mechanism of action” involving those two proprietary technologies.
- Notably: The therapeutic is currently under clinical development for more than one inflammatory disease indication.
Explain SCHOOL.
SCHOOL targets receptors—such as TREM-1—on immune cells to disrupt intracellular signaling (instead of blocking ligands like anti-vascular growth factors [VEGFs] outside of the cell).
- What makes it unique: SCHOOL works to modulate signaling at the receptor complex level—operating inside the membrane signaling process.
- And for ROP: This could translate to a more selective immune modulation and potential to simultaneously impact multiple downstream pathways, reducing inflammatory magnification and blocking TREM-1 signaling.
See here for a more detailed rundown on this.
And that peptide delivery platform?
This system targets specific immune cells (macrophages included), protects peptides from within the body, and enables the systemic administration of those aforementioned peptide inhibitor drugs.
- Importantly, it ensures these drugs are stable and cell-specific.
In the context of ROP: The platform works with SCHOOL to strategically and noninvasively delivers a TREM-1 inhibitor to retinal immune cells that, in turn, shuts down inflammation.
Sounds groundbreaking … so how does ODD factor into all of this?
ODD is a special regulatory status granted by the FDA for certain investigational drug candidates that demonstrate promise for diagnosing, treating, or preventing so-called “orphan” diseases.
- To note: These are classified as rare, serious, or life-threatening diseases or conditions (such as Stargardt) that affect <200,000 patients in the United States.
And what advantages come with this designation?
While candidates deemed to be “orphan drugs” undergo the same scientific review process as any other drug seeking regulatory approval for commercial licensing in the United States, they are also qualified to receive:
- Tax credits for qualified clinical trials
- User fees exemption
- Potential 7 years of market exclusivity following approval
Duly noted. And in the context of the TREM-1 inhibitor?
SignaBlok plans to present its first batch of preclinical efficacy pharmacokinetic and tolerability data at the upcoming 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting (May 3-7) in Denver, Colorado.
Per the company: The inhibitor’s performance was “favorable.”
Nice! And in the meantime, is there any other prior data on the therapeutic?
Not among humans … but it has reportedly undergone evaluation in an oxygen-induced retinopathy (OIR) mouse model of ROP.
The company noted that the inhibitor—which it described as a “non-toxic and well-tolerable ligand-independent TREM-1 inhibitor”—was found to significantly reduce (up to 95% retinal neovascularization in the retinas of MICE with OIR.
- This was observed during a systematic administration of the inhibitor in both preventive and therapeutic studies.
Anything else?
SignaBloc also referenced other preclinical data, which suggested the TREM-1 inhibitor could “restore retinal function and preserve vision.”
- To note: We were unable to view the details of this ROP data, as it does not appear to be publicly available.
However: Recent clinical findings can be seen here on its performance for oncology and inflammatory disease.